Camp4 Therapeutics Corporation
CAMP
$1.99
-$0.0038-0.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 652.00K | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 652.00K | -- | -- | -- | 0.00 |
| Cost of Revenue | 10.00M | 9.70M | 9.56M | 9.56M | 10.66M |
| Gross Profit | -9.34M | -9.70M | -9.56M | -9.56M | -10.66M |
| SG&A Expenses | 4.69M | 3.81M | 3.20M | 3.20M | 2.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.69M | 13.52M | 12.77M | 12.77M | 13.48M |
| Operating Income | -14.03M | -13.52M | -12.77M | -12.77M | -13.48M |
| Income Before Tax | -13.28M | -13.48M | -12.51M | -12.51M | -12.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.28M | -13.48M | -12.51M | -12.51M | -12.99M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.28M | -13.48M | -12.51M | -12.51M | -12.99M |
| EBIT | -14.03M | -13.52M | -12.77M | -12.77M | -13.48M |
| EBITDA | -13.62M | -13.10M | -12.34M | -12.34M | -13.04M |
| EPS Basic | -0.77 | -24.19 | -26.28 | -26.28 | -30.28 |
| Normalized Basic EPS | -0.48 | -15.12 | -16.43 | -16.43 | -18.93 |
| EPS Diluted | -0.77 | -24.19 | -26.28 | -26.28 | -30.28 |
| Normalized Diluted EPS | -0.48 | -15.12 | -16.43 | -16.43 | -18.93 |
| Average Basic Shares Outstanding | 17.25M | 557.40K | 476.20K | 476.20K | 428.90K |
| Average Diluted Shares Outstanding | 17.25M | 557.40K | 476.20K | 476.20K | 428.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |